Related Experiment Video

Updated: Aug 20, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

The therapeutic potential of agents targeting the type I insulin-like growth factor receptor

Hua Zhang1, Douglas Yee

  • 1University of Minnesota Cancer Center, MMC 806, 420 Delaware Street SE, Minneapolis, MN 55455, USA.

Expert Opinion on Investigational Drugs
|November 30, 2004
PubMed

Insights

Targeting the type I insulin-like growth factor receptor (IGF-1R) offers a promising cancer therapy strategy. This review explores IGF-1R

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The type I insulin-like growth factor receptor (IGF-1R) is a receptor tyrosine kinase.
  • Increased IGF-1R expression/activity is linked to various cancers.
  • IGF-1R regulates cancer cell proliferation, transformation, motility, and metastasis.

Purpose of the Study:

  • To review therapeutic strategies targeting IGF-1R in cancer.
  • To discuss downstream signaling pathways and cancer phenotypes regulated by IGF-1R.
  • To consider the role of the insulin receptor in IGF action.

Main Methods:

  • Review of existing literature on IGF-1R signaling and cancer.
  • Analysis of various inhibitory strategies for IGF-1R.
  • Discussion of clinical trial considerations for IGF-1R-targeted therapies.

Main Results:

  • IGF-1R is a validated target for cancer therapy.
  • Multiple therapeutic strategies exist, including small-molecule inhibitors, monoclonal antibodies, and ligand neutralization.
  • Understanding downstream pathways and potential cross-talk with insulin receptors is crucial.

Conclusions:

  • IGF-1R targeted therapies hold significant promise for cancer treatment.
  • Careful consideration of clinical trial design is essential for successful therapeutic development.
  • Inhibiting IGF-1R function through various mechanisms represents a viable approach to cancer therapy.

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...